MedImmune next-generation FluMist
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
MedImmune has initiated a pivotal Phase III head-to-head study comparing its next-generation, refrigerator-stable formulation of its intranasal flu vaccine FluMist to the trivalent injectable vaccine, the firm says Oct. 20. FluMist is a frozen, live, attenuated trivalent vaccine. The double-blind study will enroll 7,000 children between the ages of 6 and 59 months. A bridging study is also being conducted to establish the new cold-adapted intranasal formulation (CAIV-T) as equivalent to frozen FluMist. MedImmune has already conducted two Phase III trials in 4,400 children with a history of respiratory illness or asthma; data were presented at the Pediatric Academic Societies' annual meeting in May...
You may also be interested in...
At-Home Health Testing Demand Is High Post-Pandemic, But So Are Barriers To Development And Use
At the recent Precision Med-Tri Con conference, laboratory experts traded views on the expansion of at-home testing for disease diagnosis and personalized health insights. While strong consumer demand spells opportunity, there are significant concerns about the accuracy and reliability of home-testing platforms, misuse, accessibility, and lack of health literacy.
Simplified Clinical Trial Transparency Rules To Go Live In The EU In June
A new version of the EU Clinical Trials Information System’s public portal will integrate the functionalities of the streamlined transparency rules.
Top-Selling Drugs 2023: Pharma’s $60bn COVID-19 Cliff
Pfizer/BioNTech’s COVID-19 vaccine Comirnaty toppled after recording the highest ever annual sales for a pharmaceutical in 2022, while Novo Nordisk’s Ozempic climbed rapidly. But Merck & Co’s immuno-oncology blockbuster Keytruda was secure in the number one spot in 2023 as COVID-19 receded.